Evocutis plc is pleased to announce completion of R&D and validation of its LabSkin™ full-thickness skin model for use in supporting anti-ageing claims.

Validation of the anti-ageing LabSkin™ model will provide the Cosmetics industry with valuable data for assessing trial endpoints when testing the activity of their ingredients and products. This data can be obtained prior to expensive human-use studies, significantly reducing the risk and timelines associated with traditional product development. Furthermore, users of the anti-ageing LabSkin™ model will be able to benchmark the activity of new ingredients and formulations against best-in-class products, across several recognised anti-ageing endpoints.

Through its integrated approach to skincare development, Evocutis provides a unique portfolio of testing services to take both ingredients and products from laboratory to clinical studies at the same location. Evocutis is developing the unique attributes of its LabSkin™ full-thickness skin model to reduce the risk when transitioning between simple laboratory methods and clinical studies, supporting coherent product and claims development throughout the process.

LabSkin™ is being actively promoted as an animal-replacement technology and is suitable for assessing many of the endpoints required by the cosmetic and healthcare industries for products used on skin, including irritation, sensitisation, penetration, UV damage and antimicrobial activity.

Dr. Richard Bojar, CSO of Evocutis, says: “LabSkin™ provides a highly consistent substrate, which can now be used to assess anti-ageing activity and simultaneously provide additional information on, for example, irritation and penetration, making it a valuable tool in the development of innovative products. Feedback from our customers tells us that well designed, independent scientific studies provide consumers with well-defined claims, reassurance of quality, and clarity in a congested market. This makes LabSkin™ an invaluable marketing tool.”

Evocutis is continuing its R&D programme to develop LabSkin™ as a platform-testing technology for skincare development. It is anticipated that validation of LabSkin™ for assessing skin irritation, sensitisation, penetration, UV damage, antimicrobial activity and prebiotics will be announced to the market in the coming months.
 

Click here for full press release